Clinical trial · Interventional
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This study doesn't meet NIH criteria of clinical trial study
Summary
Brief summary (as posted)
The purpose of this research study is to help us learn if an experimental imaging device called Diffuse Optical Spectroscopic Imaging (DOSI) can monitor tumor shrinkage during chemotherapy treatment and can predict if the tumor will respond to chemotherapy before the end of the treatment. This study will also help us understand the biological reason for how DOSI works.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Tumor | Breast Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DOSI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- DOSI
- interventionNames
- Device: DOSI
Primary outcomes (5)
- measure
- Concentration of oxy-hemoglobin (HbO2), in blood.
- timeFrame
- through study completion, an average of 3 years
- measure
- Concentration of deoxy-hemoglobin (HHb) in blood.
- timeFrame
- through study completion, an average of 3 years
- measure
- Concentration of total hemoglobin in blood.
- timeFrame
- through study completion, an average of 3 years
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Females between the ages of 21 and 80. Specific to Study part #1 * Diagnosed with a Breast Imaging-Reporting and Data System score of 4 or higher breast abnormality greater than 1cm in size Specific to Study part #2 * Enrolled in study part #1 * Diagnosed with histologically-proven invasive breast cancer * Prescribed neoadjuvant chemotherapy for breast cancer Exclusion Criteria: * Pregnant * Unable to give written, informed consent.
References
Publications (0)
Data not yet available